Quick Answer
LEMAITRE VASCULAR INC reported R&D Expense of $14.14 million for fiscal year 2025.
LEMAITRE VASCULAR INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $14.14M | -9.7% |
| 2024 | $15.65M | -7.8% |
| 2023 | $16.97M | +27.6% |
| 2022 | $13.29M | +12.7% |
| 2021 | $11.80M | +16.9% |
| 2020 | $10.10M | +8.9% |
| 2019 | $9.28M | +13.2% |
| 2018 | $8.20M | +23.5% |
| 2017 | $6.64M | +8.1% |
| 2016 | $6.14M | +12.1% |
| 2015 | $5.48M | +17.3% |
| 2014 | $4.67M | -10.9% |
| 2013 | $5.24M | +3.0% |
| 2012 | $5.09M | +15.1% |
| 2011 | $4.42M | -19.4% |
| 2010 | $5.49M | -7.1% |
| 2009 | $5.91M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.97M | -18.8% | -16.1% |
| June 30, 2025 | $3.54M | -17.3% | -13.5% |
| March 31, 2025 | $4.09M | +0.1% | +12.0% |
| September 30, 2024 | $3.66M | -13.4% | -14.7% |
| June 30, 2024 | $4.28M | -5.1% | +4.7% |
| March 31, 2024 | $4.09M | +5.6% | -3.1% |
| September 30, 2023 | $4.22M | +22.0% | -6.5% |
| June 30, 2023 | $4.52M | +35.0% | +16.5% |
- LEMAITRE VASCULAR INC showed a decrease of -9.7% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, LEMAITRE VASCULAR INC’s r&d expense has grown by 139.2% (from $5.91 million to $14.14 million).
- The most recent figure is from LEMAITRE VASCULAR INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: